Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Brück W[au]:

Septic encephalopathy and septic encephalitis‬‬. Tauber SC et al. Expert Rev Anti Infect Ther. (2017)

BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions. Fard MK et al. Sci Transl Med. (2017)

An updated histological classification system for multiple sclerosis lesions. Kuhlmann T et al. Acta Neuropathol. (2017)

Search results

Items: 1 to 50 of 438

1.

Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis.

Traub J, Traffehn S, Ochs J, Häusser-Kinzel S, Stephan S, Scannevin R, Brück W, Metz I, Weber MS.

Brain Pathol. 2019 Jan 31. doi: 10.1111/bpa.12711. [Epub ahead of print]

PMID:
30706542
2.

Association between pathological and MRI findings in multiple sclerosis.

Filippi M, Brück W, Chard D, Fazekas F, Geurts JJG, Enzinger C, Hametner S, Kuhlmann T, Preziosa P, Rovira À, Schmierer K, Stadelmann C, Rocca MA; Attendees of the Correlation between Pathological and MRI findings in MS workshop.

Lancet Neurol. 2019 Feb;18(2):198-210. doi: 10.1016/S1474-4422(18)30451-4. Review.

PMID:
30663609
3.

Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.

Stork L, Brück W, von Gottberg P, Pulkowski U, Kirsten F, Glatzel M, Rauer S, Scheibe F, Radbruch H, Hammer E, Stürner KH, Kaulen B, Heesen C, Hoffmann F, Brock S, Pawlitzki M, Bopp T, Metz I.

Mult Scler. 2019 Jan 18:1352458518819098. doi: 10.1177/1352458518819098. [Epub ahead of print]

PMID:
30657420
4.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

PMID:
30207920
5.

Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease.

Häusler D, Häusser-Kinzel S, Feldmann L, Torke S, Lepennetier G, Bernard CCA, Zamvil SS, Brück W, Lehmann-Horn K, Weber MS.

Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9773-9778. doi: 10.1073/pnas.1810470115. Epub 2018 Sep 7.

6.

Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy.

Fledrich R, Abdelaal T, Rasch L, Bansal V, Schütza V, Brügger B, Lüchtenborg C, Prukop T, Stenzel J, Rahman RU, Hermes D, Ewers D, Möbius W, Ruhwedel T, Katona I, Weis J, Klein D, Martini R, Brück W, Müller WC, Bonn S, Bechmann I, Nave KA, Stassart RM, Sereda MW.

Nat Commun. 2018 Aug 2;9(1):3025. doi: 10.1038/s41467-018-05420-0.

7.

The inflammatory response and neuronal injury in Streptococcus suis meningitis.

Seele J, Tauber SC, Bunkowski S, Baums CG, Valentin-Weigand P, de Buhr N, Beineke A, Iliev AI, Brück W, Nau R.

BMC Infect Dis. 2018 Jul 3;18(1):297. doi: 10.1186/s12879-018-3206-6.

8.

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy.

Rauer S, Stork L, Urbach H, Stathi A, Marx A, Süß P, Prinz M, Brück W, Metz I.

Neurology. 2018 Jul 24;91(4):e359-e363. doi: 10.1212/WNL.0000000000005854. Epub 2018 Jun 22.

PMID:
29934423
9.

Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Central Nervous System Demyelination-A Novel Disease Entity?

Weber MS, Derfuss T, Brück W.

JAMA Neurol. 2018 Aug 1;75(8):909-910. doi: 10.1001/jamaneurol.2018.1055. No abstract available.

PMID:
29913011
10.

Multiple sclerosis pathogenesis: missing pieces of an old puzzle.

Rahmanzadeh R, Brück W, Minagar A, Sahraian MA.

Rev Neurosci. 2018 Jun 8. pii: /j/revneuro.ahead-of-print/revneuro-2018-0002/revneuro-2018-0002.xml. doi: 10.1515/revneuro-2018-0002. [Epub ahead of print]

PMID:
29883325
11.

Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations.

Koelsche C, Mynarek M, Schrimpf D, Bertero L, Serrano J, Sahm F, Reuss DE, Hou Y, Baumhoer D, Vokuhl C, Flucke U, Petersen I, Brück W, Rutkowski S, Zambrano SC, Garcia Leon JL, Diaz Coronado RY, Gessler M, Tirado OM, Mora J, Alonso J, Garcia Del Muro X, Esteller M, Sturm D, Ecker J, Milde T, Pfister SM, Korshunov A, Snuderl M, Mechtersheimer G, Schüller U, Jones DTW, von Deimling A.

Acta Neuropathol. 2018 Aug;136(2):327-337. doi: 10.1007/s00401-018-1871-6. Epub 2018 Jun 7.

PMID:
29881993
12.

Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials.

Gärtner J, Chitnis T, Ghezzi A, Pohl D, Brück W, Häring DA, Karlsson G, Putzki N.

Mult Scler J Exp Transl Clin. 2018 May 25;4(2):2055217318778610. doi: 10.1177/2055217318778610. eCollection 2018 Apr-Jun.

13.

Expression of the DNA-Binding Factor TOX Promotes the Encephalitogenic Potential of Microbe-Induced Autoreactive CD8+ T Cells.

Page N, Klimek B, De Roo M, Steinbach K, Soldati H, Lemeille S, Wagner I, Kreutzfeldt M, Di Liberto G, Vincenti I, Lingner T, Salinas G, Brück W, Simons M, Murr R, Kaye J, Zehn D, Pinschewer DD, Merkler D.

Immunity. 2018 May 15;48(5):937-950.e8. doi: 10.1016/j.immuni.2018.04.005.

PMID:
29768177
14.

Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.

Deng MY, Sill M, Chiang J, Schittenhelm J, Ebinger M, Schuhmann MU, Monoranu CM, Milde T, Wittmann A, Hartmann C, Sommer C, Paulus W, Gärtner J, Brück W, Rüdiger T, Leipold A, Jaunmuktane Z, Brandner S, Giangaspero F, Nozza P, Mora J, Morales la Madrid A, Cruz Martinez O, Hansford JR, Pietsch T, Tietze A, Hernáiz-Driever P, Stoler I, Capper D, Korshunov A, Ellison DW, von Deimling A, Pfister SM, Sahm F, Jones DTW.

Acta Neuropathol. 2018 Aug;136(2):239-253. doi: 10.1007/s00401-018-1865-4. Epub 2018 May 15.

PMID:
29766299
15.

Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors.

Lange F, Kaemmerer D, Behnke-Mursch J, Brück W, Schulz S, Lupp A.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1227-1237. doi: 10.1007/s00432-018-2645-1. Epub 2018 Apr 25.

PMID:
29696364
16.

Defining distinct features of anti-MOG antibody associated central nervous system demyelination.

Weber MS, Derfuss T, Metz I, Brück W.

Ther Adv Neurol Disord. 2018 Mar 29;11:1756286418762083. doi: 10.1177/1756286418762083. eCollection 2018. Review.

17.

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis.

Akgün K, Metz I, Kitzler HH, Brück W, Ziemssen T.

Ther Adv Neurol Disord. 2018 Mar 8;11:1756286418759895. doi: 10.1177/1756286418759895. eCollection 2018.

18.

DNA methylation-based classification of central nervous system tumours.

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM.

Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.

19.

B cells in multiple sclerosis therapy-A comprehensive review.

Rahmanzadeh R, Weber MS, Brück W, Navardi S, Sahraian MA.

Acta Neurol Scand. 2018 Jun;137(6):544-556. doi: 10.1111/ane.12915. Epub 2018 Mar 7. Review.

PMID:
29512131
20.

CLIPPERS with longitudinally extensive transverse myelitis: Role of T versus B cells.

Olmes DG, Metz I, Lee DH, Rosenwald A, Doerfler A, Brück W, Linker RA.

J Neurol Sci. 2018 Feb 15;385:96-98. doi: 10.1016/j.jns.2017.12.021. Epub 2017 Dec 18. No abstract available.

PMID:
29406923
21.

Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

Stork L, Ellenberger D, Beißbarth T, Friede T, Lucchinetti CF, Brück W, Metz I.

JAMA Neurol. 2018 Apr 1;75(4):428-435. doi: 10.1001/jamaneurol.2017.4842.

22.

Interferon beta-1b in treatment-naïve paediatric patients with relapsing-remitting multiple sclerosis: Two-year results from the BETAPAEDIC study.

Gärtner J, Brück W, Weddige A, Hummel H, Norenberg C, Bugge JP; BETAPAEDIC Study Group.

Mult Scler J Exp Transl Clin. 2017 Dec 26;3(4):2055217317747623. doi: 10.1177/2055217317747623. eCollection 2017 Oct-Dec.

23.

BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions.

Fard MK, van der Meer F, Sánchez P, Cantuti-Castelvetri L, Mandad S, Jäkel S, Fornasiero EF, Schmitt S, Ehrlich M, Starost L, Kuhlmann T, Sergiou C, Schultz V, Wrzos C, Brück W, Urlaub H, Dimou L, Stadelmann C, Simons M.

Sci Transl Med. 2017 Dec 6;9(419). pii: eaam7816. doi: 10.1126/scitranslmed.aam7816.

PMID:
29212715
24.

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.

Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, Bartsch AJ, Neumann JO, Schöning T, Hüsing J, Beelte B, Kiprianova I, Roscher M, Bhat R, von Deimling A, Brück W, Just A, Frehtman V, Löbhard S, Terletskaia-Ladwig E, Fry J, Jochims K, Daniel V, Krebs O, Dahm M, Huber B, Unterberg A, Rommelaere J.

Mol Ther. 2017 Dec 6;25(12):2620-2634. doi: 10.1016/j.ymthe.2017.08.016. Epub 2017 Aug 24.

25.

Therapy of highly active pediatric multiple sclerosis.

Huppke P, Huppke B, Ellenberger D, Rostasy K, Hummel H, Stark W, Brück W, Gärtner J.

Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843. [Epub ahead of print]

PMID:
28933245
26.

Isolation of proteolytic bacteria from mealworm (Tenebrio molitor) exoskeletons to produce chitinous material.

da Silva FKP, Brück DW, Brück WM.

FEMS Microbiol Lett. 2017 Sep 15;364(17). doi: 10.1093/femsle/fnx177.

PMID:
28911186
27.

Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.

Jarius S, König FB, Metz I, Ruprecht K, Paul F, Brück W, Wildemann B.

J Neuroinflammation. 2017 Aug 29;14(1):171. doi: 10.1186/s12974-017-0929-z.

28.

Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients.

Lalive PH, Kreutzfeldt M, Devergne O, Metz I, Bruck W, Merkler D, Pot C.

J Neuroinflammation. 2017 Jul 24;14(1):144. doi: 10.1186/s12974-017-0919-1.

29.

Association of primary central nervous system vasculitis with the presence of specific human leucocyte antigen gene variant.

Kraemer M, Becker J, Horn PA, Schwitalla JC, Keyvani K, Metz I, Wegner C, Brück W, Schlamann M, Heinemann FM, Berlit P.

Clin Neurol Neurosurg. 2017 Sep;160:137-141. doi: 10.1016/j.clineuro.2017.06.009. Epub 2017 Jun 23.

PMID:
28734234
30.

Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes.

Kantorová E, Bittšanský M, Sivák Š, Baranovičová E, Hnilicová P, Nosáľ V, Čierny D, Zeleňák K, Brück W, Kurča E.

BMC Cancer. 2017 Jun 19;17(1):424. doi: 10.1186/s12885-017-3415-1. Review.

31.

Acutely damaged axons are remyelinated in multiple sclerosis and experimental models of demyelination.

Schultz V, van der Meer F, Wrzos C, Scheidt U, Bahn E, Stadelmann C, Brück W, Junker A.

Glia. 2017 Aug;65(8):1350-1360. doi: 10.1002/glia.23167. Epub 2017 May 31.

32.

A presumed antagonistic LPS identifies distinct functional organization of TLR4 in mouse microglia.

Döring C, Regen T, Gertig U, van Rossum D, Winkler A, Saiepour N, Brück W, Hanisch UK, Janova H.

Glia. 2017 Jul;65(7):1176-1185. doi: 10.1002/glia.23151. Epub 2017 May 4.

PMID:
28471051
33.

Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis.

Lagumersindez-Denis N, Wrzos C, Mack M, Winkler A, van der Meer F, Reinert MC, Hollasch H, Flach A, Brühl H, Cullen E, Schlumbohm C, Fuchs E, Linington C, Barrantes-Freer A, Metz I, Wegner C, Liebetanz D, Prinz M, Brück W, Stadelmann C, Nessler S.

Acta Neuropathol. 2017 Jul;134(1):15-34. doi: 10.1007/s00401-017-1706-x. Epub 2017 Apr 6.

34.

Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation.

Voigt D, Scheidt U, Derfuss T, Brück W, Junker A.

Int J Mol Sci. 2017 Apr 4;18(4). pii: E760. doi: 10.3390/ijms18040760.

35.

Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions.

Popescu BF, Frischer JM, Webb SM, Tham M, Adiele RC, Robinson CA, Fitz-Gibbon PD, Weigand SD, Metz I, Nehzati S, George GN, Pickering IJ, Brück W, Hametner S, Lassmann H, Parisi JE, Yong G, Lucchinetti CF.

Acta Neuropathol. 2017 Jul;134(1):45-64. doi: 10.1007/s00401-017-1696-8. Epub 2017 Mar 22.

36.

ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports.

Körtvélyessy P, Breu M, Pawlitzki M, Metz I, Heinze HJ, Matzke M, Mawrin C, Rommer P, Kovacs GG, Mitter C, Reindl M, Brück W, Wandinger KP, Lassmann H, Höftberger R, Leypoldt F.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 14;4(3):e335. doi: 10.1212/NXI.0000000000000335. eCollection 2017 May. No abstract available.

37.

Primary central nervous system vasculitis and its mimicking diseases - clinical features, outcome, comorbidities and diagnostic results - A case control study.

Becker J, Horn PA, Keyvani K, Metz I, Wegner C, Brück W, Heinemann FM, Schwitalla JC, Berlit P, Kraemer M.

Clin Neurol Neurosurg. 2017 May;156:48-54. doi: 10.1016/j.clineuro.2017.03.006. Epub 2017 Mar 8.

PMID:
28324788
38.

Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis.

Singh S, Dallenga T, Winkler A, Roemer S, Maruschak B, Siebert H, Brück W, Stadelmann C.

J Neuroinflammation. 2017 Mar 17;14(1):57. doi: 10.1186/s12974-017-0831-8.

39.

Diagnostic red flags: steroid-treated malignant CNS lymphoma mimicking autoimmune inflammatory demyelination.

Barrantes-Freer A, Engel AS, Rodríguez-Villagra OA, Winkler A, Bergmann M, Mawrin C, Kuempfel T, Pellkofer H, Metz I, Bleckmann A, Hernández-Durán S, Schippling S, Rushing EJ, Frank S, Glatzel M, Matschke J, Hartmann C, Reifenberger G, Müller W, Schildhaus HU, Brück W, Stadelmann C.

Brain Pathol. 2018 Mar;28(2):225-233. doi: 10.1111/bpa.12496. Epub 2017 Apr 6.

PMID:
28213912
40.

An updated histological classification system for multiple sclerosis lesions.

Kuhlmann T, Ludwin S, Prat A, Antel J, Brück W, Lassmann H.

Acta Neuropathol. 2017 Jan;133(1):13-24. doi: 10.1007/s00401-016-1653-y. Epub 2016 Dec 17.

PMID:
27988845
41.

Septic encephalopathy and septic encephalitis‬‬.

Tauber SC, Eiffert H, Brück W, Nau R.

Expert Rev Anti Infect Ther. 2017 Feb;15(2):121-132. doi: 10.1080/14787210.2017.1265448. Epub 2016 Dec 5. Review.

PMID:
27885885
42.

Myelinosome formation represents an early stage of oligodendrocyte damage in multiple sclerosis and its animal model.

Romanelli E, Merkler D, Mezydlo A, Weil MT, Weber MS, Nikić I, Potz S, Meinl E, Matznick FE, Kreutzfeldt M, Ghanem A, Conzelmann KK, Metz I, Brück W, Routh M, Simons M, Bishop D, Misgeld T, Kerschensteiner M.

Nat Commun. 2016 Nov 16;7:13275. doi: 10.1038/ncomms13275.

43.

The Early Adaptive Immune Response in the Pathophysiological Process of Pneumococcal Meningitis.

Ribes S, Nessler S, Heide EC, Malzahn D, Perske C, Brück W, Nau R.

J Infect Dis. 2017 Jan 1;215(1):150-158. doi: 10.1093/infdis/jiw517. Epub 2016 Oct 31.

PMID:
27803171
44.

The value of intraoperative ultrasonography during the resection of relapsed irradiated malignant gliomas in the brain.

Mursch K, Scholz M, Brück W, Behnke-Mursch J.

Ultrasonography. 2017 Jan;36(1):60-65. doi: 10.14366/usg.16015. Epub 2016 Aug 8.

45.

Synaptic pathology in the cerebellar dentate nucleus in chronic multiple sclerosis.

Albert M, Barrantes-Freer A, Lohrberg M, Antel JP, Prineas JW, Palkovits M, Wolff JR, Brück W, Stadelmann C.

Brain Pathol. 2017 Nov;27(6):737-747. doi: 10.1111/bpa.12450. Epub 2017 Mar 6.

PMID:
27706868
46.

Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases.

Bar-Or A, Hintzen RQ, Dale RC, Rostasy K, Brück W, Chitnis T.

Neurology. 2016 Aug 30;87(9 Suppl 2):S12-9. doi: 10.1212/WNL.0000000000002821. Review.

PMID:
27572856
47.

Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI - histopathological study.

Dusek P, Bahn E, Litwin T, Jabłonka-Salach K, Łuciuk A, Huelnhagen T, Madai VI, Dieringer MA, Bulska E, Knauth M, Niendorf T, Sobesky J, Paul F, Schneider SA, Czlonkowska A, Brück W, Wegner C, Wuerfel J.

Neuropathol Appl Neurobiol. 2017 Oct;43(6):514-532. doi: 10.1111/nan.12341. Epub 2016 Oct 4.

PMID:
27543917
48.

Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.

Metz I, Rieckmann P, Kallmann BA, Brück W.

Acta Neuropathol Commun. 2016 Aug 8;4(1):81. doi: 10.1186/s40478-016-0352-1. No abstract available.

49.

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis.

Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, Metz I, Blaschek A, Dick A, Brück W, Hohlfeld R, Meinl E, Kümpfel T.

Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257. doi: 10.1212/NXI.0000000000000257. eCollection 2016 Oct.

50.

Survival and Functionality of Human Induced Pluripotent Stem Cell-Derived Oligodendrocytes in a Nonhuman Primate Model for Multiple Sclerosis.

Thiruvalluvan A, Czepiel M, Kap YA, Mantingh-Otter I, Vainchtein I, Kuipers J, Bijlard M, Baron W, Giepmans B, Brück W, 't Hart BA, Boddeke E, Copray S.

Stem Cells Transl Med. 2016 Nov;5(11):1550-1561. doi: 10.5966/sctm.2016-0024. Epub 2016 Jul 11.

Supplemental Content

Support Center